Founded in San Francisco, PuraCath Medical is committed to enhancing the quality of life for dialysis patients by reducing infections. The company’s core mission is to improve patient outcomes through innovative technology. PuraCath Medical offers a proprietary UV disinfection technology designed to simplify and redefine the catheter disinfection process prior to infusion, thereby reducing the risk of infections and minimizing dependence on user compliance.
Notable affiliated individuals and investors include experienced healthcare professionals and venture capitalists dedicated to advancing medical technology. Key achievements for PuraCath Medical include the development and implementation of their UV disinfection technology, which has garnered positive feedback from both healthcare providers and patients. The overall impact of PuraCath Medical lies in its potential to significantly reduce infection rates among dialysis patients, thereby improving their quality of life and healthcare outcomes.
